Advanced Solutions
for Advanced Pathology
CD13 (SP187)
Rabbit Monoclonal Antibody
Cat. No. Description
Volume
45646 IMPATH CD13 RTU R (SP187)
50 Tests
45633 CD13 RTU R (SP187)
7 ml Ready To Use
45610 CD13 0,1 R (SP187)
100 µl liquid Concentrated
45611 CD13 1 R (SP187)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic, Membranous
Control
Liver
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CD13 (aminopeptidase-N) is a transmembrane protease present in many tissues and cell types (e.g., endothelial and epithelial cells, fibroblasts,
and leukocytes). CD13 is overexpressed in various solid and hematological malignancies in humans, including acute myeloid leukemia (AML), and
is thought to influence tumor progression. Acute promyelocytic leukemia, hypogranular variant, poses difficulties in morphologic interpretation
for separation from other subtypes of AML. CD13 is overexpressed in the tumor and is useful in diagnosing this variant by using a panel including
antibodies against CD13(+), CD34(+), CD117(+), CD16(-), and CD33(+). Myeloid sarcoma (also called chloroma, extramedullary sarcoma, or
granulocytic sarcoma) is essentially a solid tumor composed of myeloblasts or immature myeloid cells in an extramedullary site. It can be
isolated or occur during the course of AML, chronic myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasias. Myeloid
sarcoma should be distinguished from large cell lymphoma, lymphoblastic lymphoma, Burkitt lymphoma, undifferentiated carcinoma, malignant
melanoma, extra-medullary hematopoiesis, and inflammation. Immunochemical analyses are needed for the accurate diagnosis of myeloid
sarcoma. CD13 is overexpressed in myeloid sarcoma and anti-CD13 is very useful in diagnosing myeloid sarcoma using a panel including
antibodies against CD34, CD43, CD117, MPO, lysozyme, CD163 and CD68. It has been reported that CD13 is expressed in both normal and
neoplastic liver tissue, where it exhibits a canalicular distribution pattern similar to that seen for polyclonal CEA and CD10. Thus, anti-CD13 can
be useful as an additional marker in differentiating between HCC and non-hepatocellular neoplasms.
Leukemia
CD13
CD33
CD34
CD14
MPO CD38 CD117 CD16 CD163 CD71
Acute Myeloid Leukemia
with Minimal Differentiation
+
+
+
+
+
+
+
-
-
-
Acute Myeloid Leukemia
without Maturation
+
+
+
-
+
-
+
-
-
-
Acute Myeloid Leukemia
with Maturation
+
+
+
-
+
-
+
-
-
-
Acute Myelomonocytic
Leukemia
+
+
+/-
+
+
-
+/-
+
-
-
Acute Monoblastic and
Monocytic Leukemia
+
+
-/+
+
+/-
-
+/-
+
+
-
Acute Erythroid Leukemia
-
-
-/+
-
-
-
-/+
-
-
+
Acute Megakryoblastic
Leukemia
+/-
+/-
-
-
-
-
-
-
-
+
Acute Basophilic Leukemia
+
+
+/-
-
+/-
-
+
-
-
-
Acute Panmyelosis with
Myelofibrosis
+
+
+
-
+
-
+
-
-
-
Reference
1. Bauvois B, Dauzonne D. Med. Res. Rev.2006; 26:88–130.
53
